KAMADA » MEDIA » NEWS

NEWS


Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Jul. 20, 2017

Kamada announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).  

Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Jun. 27, 2017

Kamada announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) with the European Medicines Agency (EMA).

Kamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire

Press Release / Jun. 12, 2017

Kamada announced the receipt of an undisclosed additional milestone payment under the supply and distribution agreement with Shire for GLASSIA®, Kamada’s intravenous (IV) alpha-1 antitrypsin (AAT).

Kamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus- Host Disease

/ Jun. 7, 2017

Kamada announced that Kamada and Shire have agreed that the Investigational New Drug (IND) application approved by the U.S. Food and Drug Administration (FDA) for the Phase 2/3 study evaluating Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) will be transferred from Shire to Kamada, who will take full ownership and responsibility for the clinical development of the product in this indication.

Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director

Press Release / Jun. 5, 2017

Kamada announced today the appointment of Michal Stein, M.D., as Vice President and Medical Director for Immunology.

Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference

Press Release / May. 24, 2017

Kamada announced that a poster comprising updated data from the Company’s U.S. Phase 2 clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) was presented by Professor Mark Brantly, M.D., Vice Chair of Research, Department of Medicine, Chief Division of Pulmonary, Critical Care and Sleep Medicine, Professor of Medicine, Molecular Genetics and Microbiology at the University of Florida College of Medicine and Alpha One Foundation Research Professor, at the 2017 American Thoracic Society (ATS) International Conference, being held May 19-24 in Washington, D.C. 

Kamada Reports 2017 First Quarter Financial Results

Press Release / May. 17, 2017

Reaffirms revenue guidance of $100 million for 2017
Proprietary Products segment for 2017 projected at $76-$78 million, up at least 36% compared to
2016.

Kamada to Host First Quarter 2017 Financial Results Conference Call on May 16

/ May. 16, 2017

Link to webcast

Kamada management will host an investment community conference call on Tuesday, May 16 at 8:30am Eastern Time to discuss these results and answer questions.

Glassia (more than) half full: "Bioworld Today" features Kamada as its top-story

In The News: Bioworld Today / Mar. 20, 2017

This week's top- story is about Kamada's GVHD clinical program and other interesting clinical implications of its AAT pipeline.

Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)

Press Release / Mar. 3, 2017

The company will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.

out of 130 items.